Crossmark

Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

Crossref DOI link: https://doi.org/10.1007/s13555-024-01269-y

Published Online: 2024-10-18

Published Print: 2024-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Silverberg, Jonathan I. https://orcid.org/0000-0003-3686-7805
Wollenberg, Andreas https://orcid.org/0000-0003-0177-8722
Stein Gold, Linda https://orcid.org/0000-0002-2758-1605
Del Rosso, James https://orcid.org/0000-0003-4215-7340
Yosipovitch, Gil https://orcid.org/0000-0001-6303-1822
Lio, Peter https://orcid.org/0000-0001-7600-0152
Carrascosa, Jose-Manuel https://orcid.org/0000-0003-4266-0771
Gallo, Gaia

Ding, Yuxin

Xu, Zhenhui https://orcid.org/0000-0003-0821-1008
Casillas, Marta https://orcid.org/0000-0002-6339-5279
Pierce, Evangeline https://orcid.org/0000-0002-8287-2835
Agell, Helena

Ständer, Sonja https://orcid.org/0000-0003-3612-7786
License Information

Text and Data Mining valid from 2024-10-18

Version of Record valid from 2024-10-18
More Information

Article History

First Online: 18 October 2024